# Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID)

> **NCT02847260** · PHASE4 · COMPLETED · sponsor: **United Therapeutics** · enrollment: 39 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Remodulin

## Key facts

- **NCT ID:** NCT02847260
- **Lead sponsor:** United Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2017-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02847260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02847260, "Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02847260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*